PL3332800T3 - Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP - Google Patents

Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP

Info

Publication number
PL3332800T3
PL3332800T3 PL18153676T PL18153676T PL3332800T3 PL 3332800 T3 PL3332800 T3 PL 3332800T3 PL 18153676 T PL18153676 T PL 18153676T PL 18153676 T PL18153676 T PL 18153676T PL 3332800 T3 PL3332800 T3 PL 3332800T3
Authority
PL
Poland
Prior art keywords
methods
variable domains
single variable
immunoglobulin single
treating ttp
Prior art date
Application number
PL18153676T
Other languages
English (en)
Polish (pl)
Inventor
Christian DUBY
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PL3332800T3 publication Critical patent/PL3332800T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18153676T 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP PL3332800T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P 2014-07-30 2014-07-30
EP15729829.0A EP3154569B1 (en) 2014-06-16 2015-06-16 Immunoglobulin single variable domains for use in treating ttp
PCT/EP2015/063493 WO2015193326A1 (en) 2014-06-16 2015-06-16 Methods of treating ttp with immunoglobulin single variable domains and uses thereof
EP18153676.4A EP3332800B1 (en) 2014-06-16 2015-06-16 Immunoglobulin single variable domains for use in methods of treating ttp

Publications (1)

Publication Number Publication Date
PL3332800T3 true PL3332800T3 (pl) 2021-04-19

Family

ID=51541255

Family Applications (5)

Application Number Title Priority Date Filing Date
PL18153676T PL3332800T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP
PL15729829T PL3154569T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP
PL18153674.9T PL3335724T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP
PL18153673.1T PL3335723T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP
PL18153671T PL3366305T3 (pl) 2014-06-16 2015-06-16 Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania

Family Applications After (4)

Application Number Title Priority Date Filing Date
PL15729829T PL3154569T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w leczeniu TTP
PL18153674.9T PL3335724T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP
PL18153673.1T PL3335723T3 (pl) 2014-06-16 2015-06-16 Pojedyncze domeny zmienne immunoglobuliny do zastosowania w sposobach leczenia TTP
PL18153671T PL3366305T3 (pl) 2014-06-16 2015-06-16 Sposoby leczenia ttp za pomocą pojedyńczych immunoglobulinowych domen zmiennych i ich zastosowania

Country Status (15)

Country Link
US (5) US10858445B2 (enExample)
EP (6) EP3366305B1 (enExample)
JP (3) JP6688746B2 (enExample)
KR (2) KR102568585B1 (enExample)
CN (1) CN106559985A (enExample)
AU (2) AU2015276237B2 (enExample)
CA (1) CA2952103A1 (enExample)
ES (5) ES2881331T3 (enExample)
IL (1) IL249540B (enExample)
NL (1) NL2013007B1 (enExample)
PL (5) PL3332800T3 (enExample)
PT (5) PT3335724T (enExample)
RU (1) RU2704444C2 (enExample)
SG (2) SG11201610488QA (enExample)
WO (1) WO2015193326A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
MX2020008294A (es) * 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.
KR20220068144A (ko) * 2020-11-18 2022-05-25 주식회사 녹십자 자가 항체에 대한 회피율 또는 활성이 증가된 adamts13 변이체
KR20240058167A (ko) 2021-09-17 2024-05-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도
CN118715246A (zh) * 2021-12-10 2024-09-27 李人浩 结合血管性血友病因子(vwf)a1结构域或自动抑制模块的多肽、变体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
ATE203767T1 (de) 1992-08-21 2001-08-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
EP1198572A2 (en) 1999-08-02 2002-04-24 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004015425A1 (en) 2002-08-07 2004-02-19 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
JP2006512910A (ja) 2002-10-23 2006-04-20 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ａ３４およびａ３３様３ｄｎａ、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
RU2524129C2 (ru) 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
WO2005018629A1 (en) 2003-08-12 2005-03-03 Yarbrough William M Treatment for acne vulgaris and method of use
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006074947A2 (en) 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
EP3415535B1 (en) * 2005-05-20 2020-12-09 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
AU2009227055A1 (en) 2008-03-21 2009-09-24 Ablynx Nv Von Willebrand Factor specific binders and methods of use therefor
BRPI0919979A2 (pt) 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
MX2011004558A (es) 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
EP2506874A1 (en) 2009-12-01 2012-10-10 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
CN104800844A (zh) * 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
RU2680402C2 (ru) 2011-06-10 2019-02-21 Бакстер Интернэшнл Инк. Лечение нарушений свертываемости крови путем введения рекомбинантного фв
ES2813432T3 (es) 2011-08-17 2021-03-23 Glaxo Group Ltd Proteínas y péptidos modificados
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MX2020008294A (es) 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.

Also Published As

Publication number Publication date
PT3332800T (pt) 2020-11-19
US20180155441A1 (en) 2018-06-07
PT3335723T (pt) 2022-05-20
PL3335724T3 (pl) 2022-09-19
ES2924199T3 (es) 2022-10-05
SG10201811109PA (en) 2019-01-30
KR102403388B1 (ko) 2022-06-03
JP6688746B2 (ja) 2020-04-28
RU2017100077A (ru) 2018-07-12
AU2015276237A1 (en) 2017-01-19
JP2020097600A (ja) 2020-06-25
EP4059513A1 (en) 2022-09-21
EP3332800B1 (en) 2020-08-26
EP3335724A1 (en) 2018-06-20
EP3366305A1 (en) 2018-08-29
EP3335723A1 (en) 2018-06-20
PL3366305T3 (pl) 2021-06-14
US20180155443A1 (en) 2018-06-07
AU2021202747A1 (en) 2021-05-27
KR20170015513A (ko) 2017-02-08
US20180155440A1 (en) 2018-06-07
US10858445B2 (en) 2020-12-08
ES2915473T3 (es) 2022-06-22
KR102568585B1 (ko) 2023-08-18
SG11201610488QA (en) 2017-01-27
US20180155442A1 (en) 2018-06-07
PL3335723T3 (pl) 2022-07-18
ES2831865T3 (es) 2021-06-09
EP3154569A1 (en) 2017-04-19
US12269893B2 (en) 2025-04-08
EP3366305B1 (en) 2020-11-18
NL2013007B1 (en) 2016-07-05
JP2017519762A (ja) 2017-07-20
ES2881331T3 (es) 2021-11-29
PT3154569T (pt) 2021-06-22
EP3332800A1 (en) 2018-06-13
EP3154569B1 (en) 2021-04-21
HK1256731A1 (en) 2019-10-04
PT3366305T (pt) 2020-12-21
WO2015193326A1 (en) 2015-12-23
PL3154569T3 (pl) 2021-11-02
US20170210822A1 (en) 2017-07-27
ES2843642T3 (es) 2021-07-19
RU2019131713A (ru) 2019-11-11
IL249540A0 (en) 2017-02-28
HK1258508A1 (en) 2019-11-15
JP2022160431A (ja) 2022-10-19
CA2952103A1 (en) 2015-12-23
RU2704444C2 (ru) 2019-10-28
CN106559985A (zh) 2017-04-05
RU2017100077A3 (enExample) 2018-12-25
IL249540B (en) 2021-09-30
PT3335724T (pt) 2022-08-02
AU2021202747B2 (en) 2024-02-15
US10919980B2 (en) 2021-02-16
HK1256730A1 (en) 2019-10-04
AU2015276237B2 (en) 2021-02-25
EP3335723B1 (en) 2022-03-30
EP3335724B1 (en) 2022-06-22
KR20220053040A (ko) 2022-04-28
JP7105260B2 (ja) 2022-07-22

Similar Documents

Publication Publication Date Title
IL281755A (en) Enhanced variable complexes of immunoglobulins
IL247898A0 (en) Anti-ox40 antibodies and methods of use
IL252008A0 (en) Methods for producing bispecific domains, variants of antibodies and their use
IL250724A0 (en) Methods for treating multiple myeloma with immunomodulatory compounds in combination with antibodies
IL247699A0 (en) Preparations and methods for the treatment of kidney disorders
PL3332800T3 (pl) Pojedyncze domeny zmienne immunoglobuliny do stosowania w sposobach leczenia TTP
IL265568A (en) Methods for treating TIM-3 elevation
HK1236434A1 (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof